New long-term efficacy and safety data on KarXT in schizophrenia

New interim results from the Phase III EMERGENT-4 open-label extension trial evaluating the long-term efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults with schizophrenia were presented on Saturday at the Annual Congress of the Schizophrenia International Research Society (SIRS) in Florence, Italy, by US pharma major Bristol Myers Squibb (NYSE: BMY).

“We are pleased to see a continued and consistent meaningful reduction in symptoms of schizophrenia across 52-weeks in an outpatient setting, beyond what was seen in the short-term, in-patient five-week trials (EMERGENT-2 and EMERGENT-3),” said Dr Roand Chen,  senior vice president and head, immunology, cardiovascular and neuroscience development, at Bristol Myers Squibb. “We look forward to continued conversations with the FDA and to sharing additional data from the EMERGENT program later this year.”

Blockbuster sales forecast